1675 / 2063
ESTRO
2017
Combined chemo- and radiotherapy
treatment
• Spatial co-operation (e.g. breast carcinoma)
• Independent cell kill (e.g. Hodgkin lymphoma)
• Interaction (e.g. H&N, cervix, NSCLC)
• “diluted” toxicity (e.g. Hodgkin lymphoma)
ESTRO
2017
H&N SCC: MACH-NC
Pignon et al.,
Lancet
355: 949-955, 2000